Vueway 0.5 mmol/ml solution for injection

Patient Information Leaflet

Introduction

Package leaflet: Information for the patient

Vueway 0.5 mmol/ml injection solution

gadopiclenol

This medicinal product is subject to additional monitoring, which will allow for rapid detection of new safety information. You can help by reporting any adverse reactions you may experience. Information on how to report adverse reactions is included at the end of section 4.

Read the entire leaflet carefully before this medicine is administered to you, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor, radiologist, or pharmacist.
• If you experience any adverse effects, consult your doctor or radiologist, even if they are not listed in this leaflet. See section 4.

Contents of this leaflet

1. What Vueway is and what it is used for
2. What you need to know before you are given Vueway
3. How Vueway is administered
4. Possible side effects
5. How to store Vueway
6. Contents of the pack and other information

1. What Vueway is and what it is used for

Vueway is a contrast agent that enhances the contrast of images obtained during magnetic resonance (MR) scans. Vueway contains the active substance gadopiclenol.

It improves the visualization and delineation of abnormal structures or lesions in certain parts of the body and helps to differentiate between healthy and diseased tissue.

It is used in adults and children from birth.

It is administered as an intravenous injection. This medicine is for diagnostic use only and will only be administered by healthcare professionals experienced in clinical magnetic resonance practice.

2. What you need to know before Vueway is administered to you

Vueway must not be administered

if you are allergic to the active substance or to any of the other components of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor, radiologist, or pharmacist before you are given Vueway:

• if you have previously had a reaction to any contrast agent,
• if you have asthma,
• if you have a history of allergies (such as hay fever, hives),
• if your kidneys are not functioning properly,
• if you have had seizures or are being treated for epilepsy,
• if you have any heart or blood vessel disease.

In all these cases, your doctor will decide whether the planned examination can be performed or not. If you are given Vueway, your doctor or radiologist must take the necessary precautions and administer it under close supervision.

Your doctor or radiologist may decide to perform a blood test to check your kidney function before deciding to use Vueway, especially if you are 65 years of age or older.

Children

Since kidney function is immature in infants up to 4 weeks of age and in children up to 1 year of age, Vueway is only used in these patients after careful evaluation by the doctor.

Other medicines and Vueway

Inform your doctor, radiologist, or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

In particular, inform your doctor, radiologist, or pharmacist if you are receiving or have recently received medicines to treat heart conditions or high blood pressure, such as β-blockers, vasoactive substances, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin II receptor antagonists.

Pregnancy and breastfeeding

Pregnancy

Gadopiclenol may cross the placenta. It is not known whether it affects the unborn baby. Consult your doctor or radiologist if you are pregnant or think you might be pregnant, as Vueway should not be used during pregnancy unless strictly necessary.

Breastfeeding

Consult your doctor or radiologist if you are breastfeeding.

Your doctor will assess whether you should continue breastfeeding or interrupt it for 24 hours after receiving Vueway.

Driving and use of machines

Vueway has no or negligible effect on the ability to drive and use machines. However, if you feel unwell after the examination, you should not drive or operate machinery.

Vueway contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per 15 ml vial; this is essentially "sodium-free".

3. How Vueway will be administered to you

A healthcare professional with specialist training will inject Vueway into your vein through a small needle. Vueway may be injected manually or with an automatic injector.

Your doctor or radiologist will determine the dose you should receive and will supervise the injection.

The usual dose of 0.1 ml/kg body weight is the same for adults and children.

In children, your doctor or radiologist will use Vueway in vials with a single-use syringe to ensure greater accuracy of the injected volume.

After the injection, you will remain under supervision for at least 30 minutes. This is the period during which adverse reactions (such as allergic reactions) are most likely to occur. However, in rare cases, reactions may occur hours or even days later.

Use in patients with severe renal impairment

The use of Vueway is not recommended in patients with severe kidney problems. However, if its use is required, only a single dose should be administered during the examination, and a second injection should not be given until at least 7 days have passed.

Use in children

Since kidney function is immature in babies up to 4 weeks of age and infants up to 1 year of age, Vueway should only be used in these patients after careful evaluation by the doctor. Children should only receive one dose of Vueway per examination, and a second injection should not be administered until at least 7 days have passed.

Use in elderly patients

If you are 65 years of age or older, dose adjustment is not necessary; however, you may be given a blood test to check that your kidneys are functioning properly.

If you receive more Vueway than you should

It is very unlikely that you will receive an overdose of Vueway, as it is administered by a qualified healthcare professional. If an overdose does occur, Vueway can be removed from the body by haemodialysis (blood cleansing).

If you have any further questions about the use of this medicine, ask your doctor, radiologist, or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

After receiving Vueway, you will remain under observation. Most adverse effects occur within minutes. There is a small risk of having an allergic reaction to Vueway. These effects may occur immediately or up to seven days after the injection. These reactions can be severe and may cause shock (a type of allergic reaction that could be life-threatening).

Immediately inform your doctor, radiologist, or healthcare professional if you experience any of the following adverse effects, as they may be the first signs of shock:

• swelling of the face, lips, tongue, or throat
• dizziness (low blood pressure)
• difficulty breathing
• skin rash
• cough, sneezing, or runny nose

The possible side effects observed during clinical trials with Vueway are listed below, categorized by their likelihood:

*Reaction at the injection site may include pain, swelling, sensation of cold or warmth, hematoma, and redness.

**Allergic reactions may include: skin inflammation, skin redness, difficulty breathing, voice changes, throat tightness, throat irritation, abnormal sensation in the mouth, transient facial flushing (early reactions), and swollen eyes, swelling, rash, and itching (late reactions).

Cases of nephrogenic systemic fibrosis (NSF) (which causes skin hardening and may also affect soft tissues and internal organs) have been reported with other gadolinium-containing contrast agents, but no cases of NSF have been reported with Vueway during clinical trials.

Reporting of adverse reactions

If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction not listed in this leaflet. You may also report them directly through the national reporting system detailed in Appendix V.

By reporting adverse reactions, you can help provide more information on the safety of this medicine.

5. Storage of Vueway

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the label of the vial or the pre-filled syringe and on the cardboard box, after "EXP" or "CAD". The expiry date refers to the last day of that month.

This medicine is a clear, colourless to pale yellow solution.

Do not use this medicine if the solution is not clear or if it contains visible particles.

For vials: This medicine does not require special storage conditions.

Chemical and physical stability has been demonstrated for 24 hours at a temperature of up to 25 °C.

From a microbiological standpoint, the product should be used immediately after opening.

For pre-filled syringes: Do not freeze.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Vueway

• The active substance is gadopiclenol. Each ml of solution contains 485.1 mg of gadopiclenol (equivalent to 0.5 mmol of gadopiclenol and 78.6 mg of gadolinium).
• The other components are tetraxetan, trometamol, hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), and water for injectable preparations. See section 2 “Vueway contains sodium”.

Appearance of Vueway and contents of the pack

It is a clear, colourless to pale yellow injectable solution.

It is available in packs containing:

• 1 vial with 3, 7.5, 10, 15, 30, 50 or 100 ml of injectable solution.
• 25 vials with 7.5, 10 or 15 ml of injectable solution.
• 1 or 10 (10 x 1) pre-filled syringes with 7.5, 10 or 15 ml of injectable solution.
• 1 pre-filled syringe with 7.5, 10 or 15 ml of injectable solution with administration kit for manual injection (one extension line and one catheter).
• 1 pre-filled syringe with 7.5, 10 or 15 ml of injectable solution with administration kit for Optistar Elite injector (one extension line, one catheter and one 60 ml plastic empty syringe).
• 1 pre-filled syringe with 7.5, 10 or 15 ml of injectable solution with administration kit for Medrad Spectris Solaris EP injector (one extension line, one catheter and one 115 ml plastic empty syringe).

Only certain pack sizes may be marketed.

Marketing Authorization Holder

Bracco Imaging SPA

Via Egidio Folli, 50

20134 Milano

Italy

Manufacturer

Guerbet

16 rue Jean Chaptal

93600 Aulnay-sous-Bois

France

BIPSO GmbH

Robert-Gerwig-Strasse 4

Singen (Hohentwiel)

78224

Germany

Bracco Imaging S.p.A.

Bioindustry Park, Via Ribes 5

10010 Colleretto Giacosa (TO)

Italy

Date of the most recent review of this leaflet

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.

<------------------------------------------------------------------------------------------------------------->

This information is intended for healthcare professionals only:

For further details on how to use the medicine, please refer to section 6.6 Special precautions for disposal and other handling in the Summary of Product Characteristics of this medicine.